SELLAS Life Sciences Completes Enrollment And Reports Positive Initial Data From Phase 2a Trial Of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia

- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule 

- Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts, Respectively 

- 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Survival (OS) of 5.4 Months vs. 2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg Twice a Week Median OS Have Not Been Reached Yet 

- 100% Overall Response Rate in Patients with ASXL1 Mutation in the 30 mg BIW Cohort to Date 

- Trial Continues with Two Expansion Cohorts of Patients with ASXL1 Mutations and Myelodysplasia-Related Molecular Mutations Other Than ASXL1; Additional Update Expected in Q3 2024